# Ranibizumab "Treat and Extend" in Diabetic Macular Edma

> **NCT01297569** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01297569
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297569, "Ranibizumab "Treat and Extend" in Diabetic Macular Edma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01297569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*